news
Daiichi Sankyo and Charleston Laboratories announce collaboration
7 August 2014 | By Daiichi Sankyo
... to develop and commercialize novel, fixed-dose combination hydrocodone products for pain and opioid-induced nausea and vomiting in the US.
List view / Grid view
Daiichi Sankyo
news
Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel
24 July 2014 | By Eli Lilly and Company & Daiichi Sankyo
Revised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®)...
news
Marketing and manufacturing approval in Japan received for CANAGLU® tablets 100mg
4 July 2014 | By Daiichi Sankyo
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU® tablets 100mg (generic name: canagliflozin hydrate, hereafter, CANAGLU®) in Japan, for the treatment of patients with type 2 diabetes mellitus...
news
12th Takamine Memorial Daiichi Sankyo Prize winner announced
2 July 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that its affiliated foundation, the Daiichi Sankyo Foundation of Life Science has awarded its 12th Takamine Memorial Daiichi Sankyo Prize...
news
Daiichi Sankyo awarded a Japan Science and Technology Agency “Newly extended Technology transfer Program” Grant
11 June 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that a R&D project for a novel, versatile vaccine adjuvant for the purpose of creating a novel vaccine has been awarded a “Newly extended Technology transfer Program”...
news
Additional disclosure regarding the merger between Sun Pharma and Daiichi Sankyo’s subsidiary Ranbaxy
4 June 2014 | By Daiichi Sankyo
As announced in releases dated April 7 and 11, 2014, Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has entered into agreements with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) in connection with merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharma. Daiichi Sankyo hereby announces additional information regarding the details of this…
news
Dainippon Sumitomo Pharma and Daiichi Sankyo cooperate on lurasidone, an atypical antipsychotic agent, in four South American countries
27 May 2014 | By Daiichi Sankyo
Dainippon Sumitomo Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride...
news
Daiichi Sankyo launches the antiplatelet agent Efient® 3.75mg/5mg tablets
27 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched the antiplatelet agent Efient® 3.75mg/5mg Tablets in Japan...
news
Daiichi Sankyo receives approval in Japan for additional indication related to RANMARKⓇ for treatment of giant cell tumor of bone
23 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has received approval in Japan for partial modification to RANMARKⓇ...
news
Sanford-Burnham and Daiichi Sankyo form alliance to study novel drug targets in cardiovascular-metabolic diseases
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
news
Announcement regarding the post-evaluation result for the project of H5N1 influenza vaccine
12 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced in August 2011 that the Group company, Kitasato Daiichi Sankyo Vaccine Company Limited, had been selected for the Japanese Ministry of Health, Labour and Welfare’s cell culture vaccine production facility capacity building grant...
news
Daiichi Sankyo announces discontinuation of phase 3 clinical trial in Japan of nimotuzumab (DE-766) in Lung Cancer
25 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the discontinuation of the phase 3 clinical trial conducted in Japan for nimotuzumab (DE-766) in Lung Cancer...
news
Announcement regarding the post-evaluation result for the project of H5N1 influenza vaccine
25 April 2014 | By Daiichi Sankyo
Kitasato Daiichi Sankyo Vaccine engaged in preparations to build a scheme to supply vaccines by the end of March 2014...
news
Announcement regarding merger between Sun Pharma and Daiichi Sankyo’s subsidiary Ranbaxy and resulting change in subsidiary
11 April 2014 | By Daiichi Sankyo
As announced in a release dated April 7, 2014, pursuant to a merger transaction, whereby Daiichi Sankyo Company, Limited has agreed with Sun Pharmaceutical Industries Ltd...
news
Daiichi Sankyo agrees to vote its shares in Ranbaxy in favor of Sun Pharma’s Acquisition
7 April 2014 | By Daiichi Sankyo
Pursuant to the merger transaction announced between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd. announces that it has agreed to vote its shares in Ranbaxy in favor of Sun Pharma’s acquisition of 100%...
